XTL Biopharmaceuticals Extraordinary General Meetings Postponed Until October 10, 2008

VALLEY COTTAGE, N.Y., Oct. 2  /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that its Extraordinary General Meetings ("EGMs") were postponed until October 10, 2008 in accordance with its articles of association due to the absence of a quorum. The postponed EGMs will take place at the offices of Kantor & Co. Law Offices, 14 Abba Hillel Silver Road, Oz House, 12th Floor, Ramat Gan, Israel at 3:00 p.m. Israel time, and 5:30 p.m. Israel time, respectively, on October 10, 2008.

Any proxy votes received at any time up to 48 hours prior to the postponed EGMs will be included in the total votes counted for the EGMs. Those shareholders who have a valid "proof of ownership" in Israel or a letter of representation from Computershare, the Company's United Kingdom registrars, and attend the meeting in person will also be permitted to vote.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(TASE:XTL). 

DATASOURCE: XTL Biopharmaceuticals Ltd.



CONTACT:  Ron Bentsur, Chief Executive Officer, XTL Biopharmaceuticals

Ltd., [phone] ext. 225

Copyright